To view the content of this page, please Sign In or Register.
In this audiovisual abstract, Dr. Zarko Manojlovic discusses the findings and implications of the International Family Study’s most recent publication. This study used whole exome sequencing on familial trios from Madagascar to identify cleft variants. During analysis, novel ancestral associations were discovered and discussed.
Presented by: Zarko Manojlovic, PhD
Zarko Manojlovic currently serves two roles: (1) Assistant Professor in the Department of Translational Genomics at the University of Southern California, where he has established a rigorous preclinical research program that leverages genome-centric approaches to study molecular profiles across multiple types of disorders, and (2) Director of Keck Genomics Platform, an end-to-end high-throughput NGS sequencing facility.
Dr. Manojovic’s lab focuses on utilizing “omics” such as genomics, epigenomics, and transcriptomics to identify complex molecular events that may explain clinical outcomes. His primary research interest is identifying alterations that drive metastatic disease, the impact of tumor microenvironment, and developing diagnostic signatures of aggressive tumor subtypes. Furthermore, his research spans across other disciplines such as germline genetics, functional/translational genomics, and lastly, interrogating ancestry effects on disease progression and outcomes in multi-ethnic cohorts to address health disparities and precision medicine. His team utilizes integrative approaches such as big data wrangling, informatics, and molecular techniques in a multi-disciplinary collaborative environment to identify molecular alterations and translate these findings into new strategies to improve diagnosis and treatment.
As the Director of Keck Genomics Platform (high-throughput sequencing center), his team’s goal is to provide cutting-edge genomic service with complete high throughput next-generation sequencing workflows. In addition, to foster and engage a collaborative environment with industry and academic leaders to innovate and refine clinically relevant discoveries.
